Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

Background This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention). Methods and Results This was a pooled participant‐level analysis of the CANVAS (Canagliflozin Cardiovascular Assessment...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S. Bajaj, G. B. John Mancini, Norman C. Wong, April Slee, Fernando G. Ang, Wally Rapattoni, Brendon L. Neuen, Clare Arnott, Vlado Perkovic, Kenneth W. Mahaffey
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2024-02-01
סדרה:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
נושאים:	canagliflozin primary and secondary prevention type 2 diabetes
גישה מקוונת:	https://www.ahajournals.org/doi/10.1161/JAHA.123.031586
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!